The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99%WOBURN, Mass., April 13,…
Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ --…
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma…